Chargari Cyrus, Maroun Pierre, Lazarescu Ioana, Haie-Meder Christine
Gustave-Roussy Cancer Campus, service de curiethérapie, 114, rue Édouard-Vaillant, 94800 Villejuif, France; Gustave-Roussy Cancer Campus, radiothérapie moléculaire, UMR 1030, 114, rue Édouard-Vaillant, 94800 Villejuif, France; Institut de recherche biomédicale des armées, D19, effets biologiques des rayonnements, 91220 Brétigny-sur-Orge, France; École du Val-de-Grâce, 1, place Alphonse-Laveran, 75230 Paris cedex 05, France.
Gustave-Roussy Cancer Campus, service de curiethérapie, 114, rue Édouard-Vaillant, 94800 Villejuif, France.
Bull Cancer. 2017 Dec;104(12):1039-1045. doi: 10.1016/j.bulcan.2017.07.009. Epub 2017 Oct 31.
The adjuvant management of uterine endometrial cancer has been studied in many randomized trials, leading to define postoperative therapeutic indications, depending on the risk factors for relapse, and on the expected benefit in terms of locoregional control and survival. The potential toxicity of treatments should be also considered. We review the available literature that yielded to guidelines that were recently published, on behalf of European societies, and we highlight the perspectives on ongoing studies, aimed at better defining the place and type of adjuvant treatment.
许多随机试验对子宫内膜癌的辅助治疗进行了研究，从而根据复发风险因素以及局部区域控制和生存方面的预期获益来确定术后治疗指征。还应考虑治疗的潜在毒性。我们回顾了代表欧洲各学会最近发表的指南所依据的现有文献，并强调了正在进行的研究的前景，这些研究旨在更好地确定辅助治疗的地位和类型。
